Free Trial
NASDAQ:CABA

Cabaletta Bio Q3 2023 Earnings Report

Cabaletta Bio logo
$1.66 +0.15 (+9.60%)
As of 12:57 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cabaletta Bio EPS Results

Actual EPS
-$0.37
Consensus EPS
-$0.39
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Cabaletta Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cabaletta Bio Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Thursday, November 9, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Cabaletta Bio's Q1 2025 earnings is scheduled for Wednesday, August 6, 2025

Cabaletta Bio Earnings Headlines

A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
See More Cabaletta Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cabaletta Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cabaletta Bio and other key companies, straight to your email.

About Cabaletta Bio

Cabaletta Bio (NASDAQ:CABA) is a clinical-stage biotechnology company focused on the discovery and development of precision T cell therapies for patients with severe autoimmune and chronic inflammatory diseases. Utilizing its proprietary chimeric autoantibody receptor T cell (CAAR-T) platform, Cabaletta engineers antigen-specific T cells designed to selectively target and eliminate pathogenic, autoreactive B cells while sparing protective immune cells. The company’s lead candidate, DSG3-CAART, is currently being evaluated in patients with mucocutaneous pemphigus vulgaris, a rare and potentially life-threatening skin disorder driven by autoantibodies against desmoglein 3.

In addition to its lead program, Cabaletta is advancing a pipeline of next-generation CAAR-T and related T cell therapies for other antibody-mediated conditions including muscle-specific kinase (MuSK) myasthenia gravis and other severe autoimmunity targets. Preclinical studies indicate that the firm’s modular platform may be readily adapted to different disease-relevant antigens, offering the potential for a broad range of applications across immunological diseases. Cabaletta also maintains strategic collaborations and research partnerships to support translational studies and expand its pipeline.

Founded in 2017 as a spin-out from academic research at the University of Pennsylvania, Cabaletta Bio is headquartered in Philadelphia, Pennsylvania. The company operates a research and development hub that integrates cell engineering, translational immunology, and clinical operations. With an emphasis on rigorous scientific validation, Cabaletta has secured necessary regulatory clearances to initiate multiple early-stage clinical trials in the United States and plans to expand its trial network globally.

Led by a seasoned management team with extensive experience in cell therapy, immunology and late-stage clinical development, Cabaletta is guided by CEO David P. Lockhart, Ph.D., whose prior roles include senior leadership positions at major biotechnology and pharmaceutical companies. Supported by a board of directors and advisors comprising both industry veterans and academic experts, the company is positioned to advance its innovative T cell therapies toward potential registration and commercialization.

View Cabaletta Bio Profile

More Earnings Resources from MarketBeat